Details of the Drug Combination

General Information of Drug Combination (ID: DCRVG15)

Drug Combination Name
Taxol Vinflunine
Indication
Disease Entry Status REF
Malignant melanoma Investigative [1]
Component Drugs Taxol   DMUOT9V Vinflunine   DMTJAEP
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL
High-throughput Screening Result Testing Cell Line: UACC62
Zero Interaction Potency (ZIP) Score: 0.27
Bliss Independence Score: 2.21
Loewe Additivity Score: 1.68
LHighest Single Agent (HSA) Score: 0.88

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Taxol
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [2]
Solid tumour/cancer 2A00-2F9Z Approved [3]
Pancreatic cancer 2C10 Phase 3 [4]
Gastric adenocarcinoma 2B72 Phase 2 [5]
Ovarian cancer 2C73 Phase 2 [5]
Taxol Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Apoptosis regulator Bcl-2 (BCL-2) TTJGNVC BCL2_HUMAN Modulator [2]
Tubulin beta (TUBB) TTYFKSZ NOUNIPROTAC Modulator [2]
------------------------------------------------------------------------------------
Indication(s) of Vinflunine
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Approved [3]

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Chronic myelogenous leukemia DC02A62 K-562 Investigative [6]
Invasive ductal carcinoma DC70TZC BT-549 Investigative [7]
Adenocarcinoma DCIEOUT NCIH23 Investigative [1]
Adenocarcinoma DC8RK5R HCC-2998 Investigative [1]
Cutaneous melanoma DC8JX0C SK-MEL-28 Investigative [1]
High grade ovarian serous adenocarcinoma DCHVXR3 OVCAR-8 Investigative [1]
Lung adenocarcinoma DCAB71M HOP-62 Investigative [1]
Malignant melanoma DCN5H30 LOX IMVI Investigative [1]
Minimally invasive lung adenocarcinoma DCQZBRR NCI-H322M Investigative [1]
Non-small cell lung carcinoma DCIZYXH HOP-92 Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 10 DrugCom(s)

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
7 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.